

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/525,057
		Date Filed:	18 February 2005
		First Named Inventor	James HILL
		Group Art Unit	
		Examiner Name	
(use as many sheets as necessary)		Attorney Docket Number	41577/312173
Sheet	1	of	5

Examiner Initials *	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/BG/		WO 95/18231	07/06/1995	WIPO		
/BG/		WO 96/28551	09/19/1996	WIPO		
/BG/		WO 00/73347	12/07/2000	WIPO		
/BG/		WO 01/70200 A1	09/27/2001	WIPO		

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BG/		Anderson, et al., 'Protection of Mice from Fatal Bubonic and Pneumonic Plague by Passive Immunization with Monoclonal Antibodies Against the F1 Protein of <i>Yersinia Pestis</i> ,' <i>Am. J. Trop. Med. Hyg.</i> , 56(4):471-473 (1997)	
/BG/		Andrews, et al., 'Fraction 1 Capsular Antigen (F1) Purification from <i>Yersinia pestis</i> CO92 and from an <i>Escherichia coli</i> Recombinant Strain and Efficacy against Lethal Plague Challenge,' <i>Infection and Immunity</i> , 64(6) :2180-2187 (1996)	
/BG/		Casadevall, 'Short Analytical Review Passive Antibody Therapies: Progress and Continuing Challenges,' <i>Clinical Immunology</i> , 93(1):5-15 (1999)	
/BG/		Cornelis, 'Minireview The <i>Yersinia</i> Deadly Kiss,' <i>Journal of Bacteriology</i> , 180(21):5495-5504 (1998)	

Examiner Signature	/Brian Gangle/	Date Considered	03/16/2007
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

5

**Complete If Known**

Application Number

10/525,057

Date Filed:

18 February 2005

First Named Inventor

James HILL

Group Art Unit

Examiner Name

Attorney Docket Number

41577/312173

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BG/		de Haard, <i>et al.</i> , 'A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies,' <i>Journal of Biological Chemistry</i> , 274(26):18218-18230 (1999)	
/BG/		Du, <i>et al.</i> , 'Role of Fraction 1 Antigen of <i>Yersinia pestis</i> in Inhibition of Phagocytosis,' <i>Infection and Immunity</i> , 70(3):1453-1460 (2002)	
/BG/		Duplantier, <i>et al.</i> , 'Resurgence de la peste dans le district d'Ikongo a Madagascar en 1998,' <i>Bulletin De La Societe De Pathologie Exotique</i> , 94(2):119-112 (2001)	
/BG/		Fields, <i>et al.</i> , 'Virulence role of V antigen of <i>Yersinia pestis</i> at the bacterial surface,' <i>Infection and Immunity</i> , 67(10):5395-5408 (1999)	
/BG/		Frank, <i>et al.</i> , 'Generation and Characterization of a Protective Monoclonal Antibody to <i>Pseudomonas aeruginosa</i> PcrV,' <i>Journal of Infectious Diseases</i> , 186:64-73 (2002)	
/BG/		Green, <i>et al.</i> , 'The SCID/Beige mouse as a model to investigate protection against <i>Yersinia pestis</i> ,' <i>FEMS Immunology and Medical Microbiology</i> , 23(2):107-113 (1999)	
/BG/		Guiyoule, <i>et al.</i> , 'Recent Emergence of New Variants of <i>Yersinia pestis</i> in Madagascar,' <i>Journal of Clinical Microbiology</i> , 35(11):2826-2833 (1997)	
/BG/		Guiyoule, <i>et al.</i> , 'Transferable Plasmid-Mediated Resistance to Streptomycin in a Clinical Isolate of <i>Yersinia pestis</i> ,' <i>Emerging Infectious Diseases</i> , 7(1):43-48 (2001)	
/BG/		Heath, <i>et al.</i> , 'Protection against experimental bubonic and pneumonic plague by a recombinant capsulat F1-V antigen fusion protein vaccine,' <i>Vaccine</i> , 16(11/12):1131-1137 (1998)	
/BG/		Hill, <i>et al.</i> , 'Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of <i>Yersinia pestis</i> ,' <i>Infection and Immunity</i> , 71(4):2234-2238 (2003)	
/BG/		Hill, <i>et al.</i> , 'Regions of <i>Yersinia pestis</i> V Antigen That contribute to Protection against Plague Identified by Passive and Active Immunization,' <i>Infection and Immunity</i> , 65(11):4476-4482 (1997)	
/BG/		Hueck, 'Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants,' <i>Microbiology and Molecular Biology Reviews</i> , 62(2):379-433 (1998)	
/BG/		Jones, <i>et al.</i> , 'Protective efficacy of a fully recombinant plague vaccine in the guinea pig,' <i>Vaccine</i> , 21:3912-3918 (2003)	

Examiner  
Signature

/Brian Gangle/

Date

Considered

03/16/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 5

**Complete if Known**

Application Number	10/525,057
Date Filed:	18 February 2005
First Named Inventor	James HILL
Group Art Unit	
Examiner Name	
Attorney Docket Number	41577/312173

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BG/		Jones, <i>et al.</i> , 'Protection conferred by a fully recombinant sub-unit vaccine against <i>Yersinia pestis</i> in male and female mice of four inbred strains,' <i>Vaccine</i> , 19:358-366 (2001)	
/BG/		Keller, <i>et al.</i> , 'Passive Immunity in Prevention and Treatment of Infectious Diseases,' <i>Clin. Microbiol. Rev.</i> , 13(4):602-614 (2000)	
/BG/		Knappik, <i>et al.</i> , 'Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,' <i>Journal of Molecular Biology</i> , 296:57-86 (2000)	
/BG/		Leary, <i>et al.</i> , 'Active Immunization with Recombinant V Antigen from <i>Yersinia pestis</i> Protects Mice against Plague,' <i>Infection and Immunity</i> , 63(8):2854-2858 (1995)	
/BG/		Leary, <i>et al.</i> , 'Expression of an F1/V fusion protein in attenuated <i>Salmonella typhimurium</i> and protection of mice against plague,' <i>Microbial Pathogenesis</i> , 23:167-179 (1997)	
/BG/		Mayers, <i>et al.</i> , 'Antitoxin therapy for botulinum intoxication,' <i>Reviews in Medical Microbiology</i> , 12(1):29-37 (2001)	
/BG/		Migliani, <i>et al.</i> , 'Resurgence de la peste dans le district d'Ikongo a Madagascar en 1998,' <i>Bulletin De La Societe De Pathologie Exotique</i> , 94(2):115-118 (2001)	
/BG/		Motin, <i>et al.</i> , 'Suppression of Mouse Skin Allograft Rejection by Protein A- <i>Yersiniae</i> V Antigen Fusion Peptide,' <i>Transplantation</i> , 63(7):1040-1042 (1997)	
/BG/		Motin, <i>et al.</i> , 'Passive Immunity to <i>Yersiniae</i> Mediated by Anti-Recombinant V Antigen and Protein A-V Antigen Fusion Peptide,' <i>Infection and Immunity</i> , 62(10):4192-4201 (1994)	
/BG/		Nakajima, <i>et al.</i> , 'Suppression of Cytokines in Mice by Protein A-V Antigen Fusion Peptide and Restoration of Synthesis by Active Immunization,' <i>Infection and Immunity</i> , 63(8):3021-3029 (1995)	
/BG/		Neuberger, <i>et al.</i> , 'Mice perform a human repertoire,' <i>Nature</i> , 386:25-26 (1997)	
/BG/		Nissim, <i>et al.</i> , 'Antibody fragments from a 'single pot' phage display library as immunochemical reagents,' <i>Embo Journal</i> , 13(3):692-698 (1994)	
/BG/		Perry, <i>et al.</i> , ' <i>Yersinia pestis</i> –Etiologic Agent of Plague,' <i>Clinical Microbiology Reviews</i> , 10(1):35-66 (1997)	

Examiner  
Signature

/Brian Gangle/

Date  
Considered

03/16/2007

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5

**Complete if Known**

Application Number	10/525,057
Date Filed:	18 February 2005
First Named Inventor	James HILL
Group Art Unit	
Examiner Name	
Attorney Docket Number	41577/312173

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BG/		Pettersson, <i>et al.</i> , 'The V-antigen of <i>Yersinia</i> is surface exposed before target cell contact and involved in virulence protein translocation,' <i>Molecular Microbiology</i> , 32(5):961-976 (1999)	
/BG/		Ratsitorahina, <i>et al.</i> , 'Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar,' <i>Lancet</i> , 355:111-113 (2000)	
/BG/		Rosqvist, <i>et al.</i> , 'Intracellular Targeting of the <i>Yersinia</i> YopE Cytotoxin in Mammalian Cells Unduces Actin Microfilament Disruption,' <i>Infection and Immunity</i> , 59(12):4562-4569 (1991)	
/BG/		Rosqvist, <i>et al.</i> , 'Target cell contact triggers expression and polarized transfer of <i>Yersinia</i> YopE cytotoxin into mammalian cells,' <i>Embo Journal</i> , 13(4):964-972 (1994)	
/BG/		Russell, <i>et al.</i> , 'A comparison of Plague vaccine, USP and EV76 vaccine induced protection against <i>Yersinia pestis</i> in a murine model,' <i>Vaccine</i> , 13(16):1551-1556 (1995)	
/BG/		Sawa, <i>et al.</i> , 'Active and passive immunization with the <i>Pseudomonas</i> V antigen protects against type III intoxication and lung injury,' <i>Nature Medicine</i> , 5(4):392-398 (1999)	
/BG/		Shime, <i>et al.</i> , 'Therapeutic Administration of Anti-PcrV F(ab') <sub>2</sub> in Sepsis Associated with <i>Pseudomonas aeruginosa</i> ,' <i>Journal of Immunology</i> , 167:5880-5886 (2001)	
/BG/		Sing, <i>et al.</i> , ' <i>Yersinia enterocolitica</i> Evasion of the Host Innate Immune Response by V Antigen-Induced IL-10 Production of Macrophages Is Abrogated in IL-10-Deficient Mice,' <i>Journal of Immunology</i> , 168:1315-1321 (2002)	
/BG/		Shivaji, <i>et al.</i> , 'Identification of <i>Yersinia pestis</i> as the causative organism of plague in India as determined by 16S rDNA sequencing and RAPD-based genomic fingerprinting,' <i>FEMS Microbiology Letters</i> , 189:247-252 (2000)	
/BG/		Taylor, <i>et al.</i> , 'Humanised monoclonal antibody to respiratory syncytial virus,' <i>Lancet</i> , 337:1411-1412 (1991)	
/BG/		Titball, <i>et al.</i> , 'Expression of the <i>Yersinia pestis</i> Capsular Antigen (F1 Antigen) on the Surface of an <i>aroA</i> Mutant of <i>Salmonella typhimurium</i> Induces High Levels of Protection against Plague,' <i>Infection and Immunity</i> , 65(5):1926-1930 (1997)	

Examiner Signature	/Brian Gangle/	Date Considered	03/16/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

5

**Complete if Known**

Application Number	10/525,057
Date Filed:	18 February 2005
First Named Inventor	James HILL
Group Art Unit	
Examiner Name	
Attorney Docket Number	41577/312173

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BG/		Titball, <i>et al.</i> , 'Vaccination against bubonic and pneumonic plague,' <i>Vaccine</i> , 19:4175-4184 (2001)	
/BG/		Weeks, <i>et al.</i> , 'Anti-V antigen antibody protects macrophages from <i>Yersinia pestis</i> -induced cell death and promotes phagocytosis,' <i>Microbial Pathogenesis</i> , 32:227-237 (2002)	
/BG/		Welkos, <i>et al.</i> , 'V antigen of <i>Yersinia pestis</i> inhibits neutrophil chemotaxis,' <i>Microbial Pathogenesis</i> , 24:185-196 (1998)	
/BG/		Williamson, <i>et al.</i> , 'A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague,' <i>Vaccine</i> , 15(10):1079-1084 (1997)	
/BG/		Williamson, <i>et al.</i> , 'An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model,' <i>Clinical and Experimental Immunology</i> , 116:107-114 (1999)	
/BG/		Williamson, <i>et al.</i> , 'Plague vaccine research and development,' <i>Journal of Applied Microbiology</i> , 91:606-608 (2001)	
/BG/		Williamson, <i>et al.</i> , 'A single dose sub-unit vaccine protects against pneumonic plague,' <i>Vaccine</i> , 19:566-571 (2000)	
/BG/		Williamson, <i>et al.</i> , 'A new improved sub-unit vaccine for plague: the basis of protection,' <i>FEMS Immunology and Medical Microbiology</i> , 12:223-230 (1995)	
/BG/		Winter, <i>et al.</i> , 'Antibody-based therapy Humanized antibodies,' <i>Trends in Pharmacological Sciences</i> , 14:139-143 (1993)	
/BG/		Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry "Formulation," Volume 5, pp. 567-591 (Corwin Hansch; Chairman of Editorial Board, Pergamon Press) (1990)	

Examiner  
Signature

/Brian Gangle/

Date  
Considered

03/16/2007

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.